Shares in Aliso Viejo-based Aeon Biopharma are up 19% after receiving positive feedback from the FDA regarding its ABP-450, a biosimilar to Botox.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.